Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Genistein nanoparticle - Humanetics Corporation

Next Previous
X
Search
Drug Profile

Genistein nanoparticle - Humanetics Corporation

Alternative Names: BIO-300

Latest Information Update: 13 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Armed Forces Radiobiology Research Institute; National Institutes of Health (USA); United States Department of Defense
  • Developer Armed Forces Radiobiology Research Institute; Henry Ford Health System; Humanetics Corporation; Medical College of Wisconsin; Milwaukee VA Medical Center; National Institutes of Health (USA); University of Maryland, Baltimore
  • Class Antifibrotics; Antineoplastics; Chemosensitisers; Isoflavones; Osteoporosis therapies; Phytotherapies; Radioprotectives; Small molecules
  • Mechanism of Action Antioxidants; Apoptosis inhibitors; Apoptosis stimulants; Cell cycle modulators; DNA repair enzyme modulators; Haematopoietic cell growth factor stimulants; Inflammation mediator modulators; Protein tyrosine kinase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pulmonary fibrosis
  • Phase I/II Radiation injuries
  • Phase I Acute radiation syndrome

Most Recent Events

  • 09 Aug 2024 Minneapolis-based Humanetics Corporation (Humanetics) entered into cooperative research agreement with Armed Forces Radiobiology Research Institute (AFRRI) to continue advanced development of BIO 300
  • 19 Sep 2023 Efficacy, pharmacokinetics and adverse events data from a phase-I/II trial in Radiation injuries released by Humanetics Corporation
  • 24 May 2023 Pharmacodynamics data from a non-clinical trial in Radiation injuries released by Humanetics Corporation

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top